| 13.065 0.375 (2.96%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 15.83 |
1-year : | 16.71 |
| Resists | First : | 13.55 |
Second : | 14.31 |
| Pivot price | 13.41 |
|||
| Supports | First : | 12.34 | Second : | 10.26 |
| MAs | MA(5) : | 13.02 |
MA(20) : | 13.3 |
| MA(100) : | 11.97 |
MA(250) : | 9.77 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 25.8 |
D(3) : | 32.8 |
| RSI | RSI(14): 45.8 |
|||
| 52-week | High : | 15.89 | Low : | 6.46 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BVS ] has closed above bottom band by 27.4%. Bollinger Bands are 32.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.11 - 13.19 | 13.19 - 13.27 |
| Low: | 12.46 - 12.55 | 12.55 - 12.64 |
| Close: | 12.92 - 13.06 | 13.06 - 13.19 |
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Mon, 28 Sep 2026
Bioventus Inc. (NASDAQ:BVS) Stock Now Rated "Moderate Buy" by Wall Street Analysts - MarketBeat
Mon, 21 Sep 2026
Bioventus: Cash Flow Anchors The Bull Case Beyond A Potential Sale (NASDAQ:BVS) - Seeking Alpha
Mon, 10 Aug 2026
Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings - Yahoo Finance
Mon, 10 Aug 2026
The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance - Yahoo Finance
Fri, 07 Aug 2026
Is Bioventus (BVS) Stock Undervalued Right Now? - Yahoo Finance
Wed, 05 Aug 2026
Bioventus Inc (BVS) (Q2 2026) Earnings Call Highlights: Strategic Review and Strong HA Growth ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 68 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 11.6 (%) |
| Held by Institutions | 83.1 (%) |
| Shares Short | 2,330 (K) |
| Shares Short P.Month | 2,730 (K) |
| EPS | 0.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.34 |
| Profit Margin | 9.3 % |
| Operating Margin | 12.2 % |
| Return on Assets (ttm) | 5.4 % |
| Return on Equity (ttm) | 25.6 % |
| Qtrly Rev. Growth | 3.7 % |
| Gross Profit (p.s.) | 5.84 |
| Sales Per Share | 8.51 |
| EBITDA (p.s.) | 1.17 |
| Qtrly Earnings Growth | 327.2 % |
| Operating Cash Flow | 97 (M) |
| Levered Free Cash Flow | 68 (M) |
| PE Ratio | 16.75 |
| PEG Ratio | 1.5 |
| Price to Book value | 3.9 |
| Price to Sales | 1.53 |
| Price to Cash Flow | 9.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|